What is the efficacy of temsirolimus (Torisel) in the treatment of renal cell carcinoma (RCC)?

Updated: Feb 19, 2021
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

Temsirolimus has been tested alone and in conjunction with interferon in patients with poor-prognosis, advanced renal cell carcinoma. Temsirolimus monotherapy at an IV dose of 25 mg weekly resulted in longer overall and progression-free survival (median survival, 10.9 mo) compared with interferon (median survival, 7.3 mo). [42] There was no significant additive effect of interferon combined with temsirolimus. A second study combining temsirolimus and interferon over a range of dose levels showed overall survival of 18.8 months and progression-free survival of 9.1 months for the combination. [43] Partial response was observed in 8% and stable disease in 36% of patients.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!